Form 4: Teladoc Health Executive Stephany Verstraete Acquires 46,700 Restricted Stock Units

Teladoc Health's Chief Marketing Officer, Stephany Verstraete, was granted 46,700 restricted stock units (RSUs) on March 19, 2024, according to a recent SEC filing.

Summary

• Stephany Verstraete, Chief Marketing Officer of Teladoc Health, Inc., acquired 46,700 restricted stock units (RSUs) on March 19, 2024.
• Each RSU represents a contingent right to receive one share of Teladoc common stock.
• The RSUs vest over time, with one-third vesting on the first anniversary of the grant date.
• The remaining RSUs vest in eight substantially equal quarterly installments starting on June 1, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, aligning interests with shareholders.

Positives

• The grant of RSUs aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.

Future Outlook

The vesting schedule of the RSUs suggests a commitment to Teladoc's long-term performance.

Industry Context

Equity compensation is a common practice in the healthcare technology industry to attract and retain top talent.

Comparison to Industry Standards

• Companies like Amwell and Accolade also use stock-based compensation to incentivize their executives.
• The vesting schedule is fairly standard, aligning with typical industry practices for RSU grants.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns executive compensation with company performance.
• Employees may see it as a sign of confidence in the company's future.

Key Dates